Restoring Quality of Life and Hematologic Function with Ibrutinib in Treatment-Naive Patients with Chronic Lymphocytic Leukemia in the RESONATE-2 Study

October 2016 Vol 7, No 9

Categories:

Clinical Research

Objectives: Disease symptoms and treatment complications can profoundly affect quality of life (QOL) in patients (pts) with chronic lymphocytic leukemia (CLL). Ibrutinib (ibr), a B-cell receptor pathway inhibitor, improved QOL in pts with relapsed/refractory CLL. Frontline ibr versus chlorambucil (clb) has also shown impressive single-agent efficacy and acceptable safety in a randomized phase 3 study (RESONATE-2) in older CLL pts; ibr reduced the risk of progression or death by 91% and the risk of death by 84% versus clb. Here, we compare the QOL and hematologic function of patients treated with frontline ibr versus clb.

Methods: In RESONATE-2, patients aged _65 years were randomized to ibr (420 mg [3 capsules] once daily until disease progression [n = 136]), or clb (0.5-0.8 mg/kg on days 1-15 of 28-day cycles for up to 12 cycles [n = 133]). Well-being was evaluated by measuring improvements in patient-reported outcomes (FACIT-Fatigue and EORTC-QLQ-C30), hematologic function, and disease symptoms.

Results: Overall response rate for ibr was 86% versus 35% with clb. Patients treated with ibr versus clb reported greater improvements in fatigue (P = .0004) and global health status (P = .0002). Sustained improvement in hematologic function occurred in 84% of ibr-treated patients with baseline anemia and 77% with baseline thrombocytopenia versus 45% and 43%, respectively, with clb. Median time to first sustained improvements in hemoglobin and platelet counts occurred 8 months earlier with ibr than with clb. Disease symptoms (fatigue, night sweats, and weight loss) improved more frequently with ibr versus clb. The most frequent adverse events (AEs) with ibr included diarrhea, fatigue, cough, and nausea and were largely mild (grade 1) versus clb, which included nausea, fatigue, neutropenia, anemia, and vomiting. Grade _3 AEs with ibr were most common in the first 6 months and generally decreased over time. AEs leading to discontinuation or dose reduction of ibr were infrequent, and 87% of patients were continuing ibr at end of the study.

Conclusion: Ibr improves QOL and hematologic function while prolonging survival. It is critical that nurse navigators educate their ibr patients about the potential improvement in survival and efficacy that they are likely to experience. Because most AEs are grade 1 and manageable, nurse navigators should provide guidance on symptom intervention and management to ensure that patients are able to adhere to their ibr regimen. Patients should also be informed about the importance of continuing ibr at the recommended, once-daily dose to maximize the likelihood of benefit.

Sponsor: Pharmacyclics LLC, and AbbVie Company.

Related Articles
Upper Gastrointestinal (GI) Morbidity and Gastric Acid–Reducing Agent (GARA) Use Among Oncolytic-Treated Patients with Non-Hodgkin Lymphomas: Nursing Perspective Insights
November 2022 Vol 13, No 11
To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.
Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE-TN)
P Walker , JP Sharman, W Jurczak, T Munir, V Banerji, S Coutre, JA Woyach, G Salles, WG Wierda, P Patel, MH Wang, U Emeribe, E Flood, JC Byrd, P Ghia
|
December 2021 Vol 12, No 12
Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Up to 7 Years of Follow-Up from the Phase 3 RESONATE-2 Study
Cara McGowan, NP, Jillian Settlemire, RN, Anita Szoke, MD, Gabriel Krigsfeld, PhD, Steven Coutre, MD, Paul Barr, MD
|
December 2021 Vol 12, No 12
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country